Catalyst Pharmaceutical CPRX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's retained earnings?
- Catalyst Pharmaceutical (CPRX) reported retained earnings of $523.35M in Q1 2026.
- How has Catalyst Pharmaceutical's retained earnings changed year-over-year?
- Catalyst Pharmaceutical's retained earnings increased by 53.1% year-over-year, from $341.9M to $523.35M.
- What is the long-term trend for Catalyst Pharmaceutical's retained earnings?
- Over 5 years (2020 to 2025), Catalyst Pharmaceutical's retained earnings has grown at a 54.6% compound annual growth rate (CAGR), from -$53.71M to $474.19M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.